| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
20/20 Biolabs, Inc. Common Stock$0.45
-0.05 (-9.71%)
Market Cap
19.63 M
EPS
-
P/E Ratio
-
Value Trade
66.73 K
SEC Financials
Q1 2026Dilution Risk
Revenue
353.38 K
R&D Expenses
153.48 K
Operating CF
-1.29 M
Total Assets
5.80 M
Total Liabilities
3.05 M
Equity
2.55 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
4.22 M
Monthly Burn
430.00 K
Runway
7.8 mo
Burn Trend
SEC Filing
May 20, 2026
Overview
Volume
142.48 K
52 Week Range
1.51 - 50
% held by Insiders
33.61 %
% held by Institutions
2.46 %
Enterprise Value
20.01 M
Total Shares
12.25 M
Short %
3.06 %
Float Shares
10.17 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AIDX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AIDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-AIDX
Jul 27, 2026▼ -9.7%today
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
20/20 BioLabs participated in BIO Asia-Taiwan and held strategic meetings in East Asia to explore acquisition and partnership opportunities. The company aims to enhance its mission of early disease detection through collaborations with local firms. CEO Jonathan Cohen emphasized the importance of these relationships for achieving Medicare reimbursement for their multi-cancer early detection test by 2028.
Read more →-AIDX
Jul 23, 2026▼ -6.8%on this news
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
20/20 BioLabs has entered a standstill agreement with Streeterville Capital regarding its Series E Convertible Preferred Stock. This agreement restricts the conversion of preferred stock into common stock unless certain price thresholds are met, thereby mitigating potential dilution. The agreement is effective for 120 days, after which normal conversion activities may resume.
Read more →-AIDX
Jul 9, 202620/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
20/20 BioLabs presented its strategy for advancing OneTest™ for Cancer during an investor webinar. The company aims to position the test for Medicare reimbursement under new legislation for multi-cancer early detection blood tests. While the approach shows promise, it faces significant regulatory hurdles, including the need for FDA authorization and CMS coverage determinations.
Read more →-AIDX
Jun 22, 202620/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
20/20 BioLabs has announced a new monthly investor webinar series starting July 1, 2026. The initiative aims to enhance transparency and communication with shareholders by providing direct access to management. Each session will last approximately 45 minutes and will include updates on the company's progress. Attendees will receive a promotional discount for a blood test.
Read more →-AIDX
May 22, 2026▼ -18.7%on this news
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
20/20 Biolabs is preparing for potential Ebola and Hantavirus testing in response to recent outbreaks. Drawing on its COVID-19 testing experience, the company is developing contingency plans and engaging with global PCR test kit developers. This proactive approach aims to ensure readiness for any surge in testing demands, although no regulatory authorization has been granted yet.
Read more →-AIDX
May 20, 2026BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Pri
20/20 BioLabs, Inc. (AIDX) reported its first quarter financial results for 2026, highlighting a decrease in revenue to $0.4 million. The company noted a significant $5.0 million private placement aimed at strengthening its cash position to $4.2 million. Noteworthy operational progress includes new distribution agreements and the launch of the OneTest for Longevity product. Despite a loss of $2.2 million during the quarter, the projected expansion of firefighter cancer screening initiatives is expected to drive future revenue growth.
Read more →-AIDX
Mar 31, 2026▲ +5.6%on this news
BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-F
20/20 BioLabs, Inc. reported its financial results for FY 2025, highlighting a 17% revenue increase to $2.0 million and a significant gross profit rise of 68%. The company's gross margin expanded notably, driven by the success of its OneTest suite of products in the expanding Multi-Cancer Early Detection (MCED) market. Despite improvements, the company also recorded a net loss of $3.7 million. Future growth is anticipated through state-funded cancer screening initiatives and new offerings such as the OneTest for Longevity.
Read more →-AIDX
Mar 27, 2026Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
20/20 BioLabs announced that 18 Maryland fire departments will receive over $520,000 for cancer screenings using their OneTest™ multi-cancer early detection blood test. This funding, part of a state initiative, aims to screen over 1,400 firefighters, highlighting the growing support for innovative cancer detection. The initiative reflects a 225% increase in funding compared to the previous year.
Read more →-AIDX
Mar 24, 2026▼ -17.6%on this newsshared move
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
20/20 BioLabs has entered an exclusive U.S. license agreement with ROKIT Healthcare to incorporate a chronic kidney disease (CKD) prediction algorithm into its Longevity Platform. This partnership aims to enhance disease-risk assessment tools, potentially improving therapeutic outcomes for patients. The agreement also includes provisions for ROKIT to commercialize the platform in Korea and other East Asian markets.
Read more →-AIDX
Feb 25, 2026▼ -28.8%on this news· ran to -58% by day 3
20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities
20/20 BioLabs has launched the OneTest for Longevity, a blood test that uses IBM's AI technology to assess chronic disease risks. This test analyzes inflammatory biomarkers and provides personalized dietary recommendations. The collaboration with DAISource aims to enhance healthcare applications through AI. However, the test is not FDA approved.
Read more →-AIDX
Feb 20, 2026▼ -38%on this news· ran to -76% by day 3shared move
20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time
20/20 BioLabs, Inc. will hold a virtual investor webinar on February 26, 2026, at 2:00 p.m. ET. CEO Jonathan Cohen will discuss the company's recent Nasdaq listing and its AI-powered blood tests, including the OneTest for Cancer and the upcoming OneTest for Longevity. A Q&A session will follow the presentation.
Read more →Competitive Position
How AIDX ranks across every disease it competes inCompetitive Position is a premium feature
See how AIDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial